AUDREY YUNG: Open Payments
NPI 1053082628 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$658 in 41 payments from 14 companies in 2025. Trend: 2023 $1,054 · 2024 $377 · 2025 $658
Food & beverage: $645Education: $13
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 15 | $164 |
| Vifor Pharma, Inc. | 9 | $153 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $61 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $49 |
| AKEBIA THERAPEUTICS INC | 2 | $41 |
| Travere Therapeutics, Inc. | 1 | $34 |
| KYOWA KIRIN, INC. | 1 | $28 |
| AstraZeneca Pharmaceuticals LP | 1 | $25 |
| Amgen Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
Products named: Veltassa, JYNARQUE, JARDIANCE, Kerendia, Vafseo, CRYSVITA, FARXIGA, TAVNEOS.
Industry payments across NV — which companies pay providers there.
